Form 8-K

8-K — SelectQuote, Inc.

Accession: 0001794783-26-000027

Filed: 2026-05-05

Period: 2026-05-05

CIK: 0001794783

SIC: 6411 (INSURANCE AGENTS BROKERS & SERVICES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — slqt-20260505.htm (Primary)

EX-99.1 (selectquoteincmarch312026pr.htm)

EX-99.2 (selectquoteincmarch31202.htm)

GRAPHIC (selectquoteincmarch31202001.jpg)

GRAPHIC (selectquoteincmarch31202002.jpg)

GRAPHIC (selectquoteincmarch31202003.jpg)

GRAPHIC (selectquoteincmarch31202004.jpg)

GRAPHIC (selectquoteincmarch31202005.jpg)

GRAPHIC (selectquoteincmarch31202006.jpg)

GRAPHIC (selectquoteincmarch31202007.jpg)

GRAPHIC (selectquoteincmarch31202008.jpg)

GRAPHIC (selectquoteincmarch31202009.jpg)

GRAPHIC (selectquoteincmarch31202010.jpg)

GRAPHIC (selectquoteincmarch31202011.jpg)

GRAPHIC (selectquoteincmarch31202012.jpg)

GRAPHIC (selectquoteincmarch31202013.jpg)

GRAPHIC (selectquoteincmarch31202014.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: slqt-20260505.htm · Sequence: 1

slqt-20260505

0001794783false00017947832026-05-052026-05-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________

FORM 8-K

_______________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2026

_____________________________________

SELECTQUOTE, INC.

(Exact name of registrant as specified in its charter)

_____________________________________

Delaware

001-39295

94-3339273

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

6800 West 115th Street, Suite 2511

Overland Park, Kansas 66211

(Address of principal executive offices) (Zip code)

(913) 599-9225

(Registrant’s telephone number, including area code)

No change since last report

(Former Name or Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol Name of each exchange on which registered

Common Stock, $0.01 par value SLQT New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 5, 2026, SelectQuote, Inc. reported its financial results for the third quarter ended March 31, 2026. Copies of the related press release and investor presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

These exhibits are being furnished pursuant to Item 2.02, and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall either of them be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description of Exhibit

99.1

Press Release

99.2

Investor Presentation

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SELECTQUOTE, INC.

Date: May 5, 2026

By: /s/ Ryan M. Clement

Name: Ryan M. Clement

Title: Chief Financial Officer

EX-99.1

Filename: selectquoteincmarch312026pr.htm · Sequence: 2

Document

Exhibit 99.1

SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2026 Results

Third Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights

•Revenue of $430.9 million

•Net income of $40.2 million

•Adjusted EBITDA* of $44.6 million

Fiscal Year 2026 Guidance Ranges:

•Revenue expected in a range of $1.61 billion to $1.71 billion

•Adjusted EBITDA* expected in a range of $90 million to $100 million

Third Quarter Fiscal Year 2026 – Segment Highlights

Senior

•Revenue of $182.9 million

•Adjusted EBITDA of $58.6 million

•Approved Medicare Advantage policies of 175,557

Healthcare Services

•Revenue of $199.4 million

•Adjusted EBITDA of $5.3 million

•116,616 SelectRx members

Life

•Revenue of $47.9 million

•Adjusted EBITDA of $6.1 million

OVERLAND PARK, Kan., May 5, 2026--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2026 of $430.9 million compared to consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million. Consolidated net income for the third quarter of fiscal year 2026 was $40.2 million compared to consolidated net income for the third quarter of fiscal year 2025 of $26.0 million. Finally, consolidated Adjusted EBITDA* for the third quarter of fiscal year 2026 was $44.6 million compared to consolidated Adjusted EBITDA* for the third quarter of fiscal year 2025 of $37.7 million.

SelectQuote Chief Executive Officer Tim Danker remarked, “SelectQuote delivered consistent profit and cash flow for another quarter, despite market shifts for both Medicare Advantage and prescription drugs. We reaffirm our financial outlook for fiscal 2026 driven by operating execution by our agents and continued leverage of our information and technology advantages. Revenue to customer acquisition cost of 6.7X represented a high water mark for the company, and more importantly, signals the value our differentiated healthcare service model provides to policyholders and prescription drug customers.”

Mr. Danker continued, “Our goal to drive reliable and consistent profit, and cash flow growth remains priority number one. We believe the improvement to our capital structure to date, combined with the continued maturation of our SelectRx business, positions SelectQuote to materially expand cash flow in the years ahead. We continue to grow our receivables balance, which now stands at nearly $1 billion and grew by nearly $50 million over the past year, including a $14 million positive change in estimate reflective of the durability and dependability of these future cash flows.”

* See “Non-GAAP Financial Measures” below.

Segment Results

We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount.

Senior

Financial Results

The following table provides the financial results for the Senior segment for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

(in thousands) 2026 2025 % Change 2026 2025 % Change

Revenue $ 182,890 $ 169,442 8 % $ 503,426 $ 517,930 (3) %

Adjusted EBITDA 58,642 45,701 28 % 140,057 153,949 (9) %

Adjusted EBITDA Margin 32 % 27 % 28 % 30 %

Operating Metrics

Submitted Policies

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

2026 2025 % Change 2026 2025 % Change

Medicare Advantage 196,970 201,817 (2) % 553,286 588,872 (6) %

All other (1)

24,912 22,858 9 % 71,632 65,975 9 %

Total 221,882 224,675 (1) % 624,918 654,847 (5) %

(1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

Approved Policies

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

2026 2025 % Change 2026 2025 % Change

Medicare Advantage 175,557 168,001 4 % 495,346 507,530 (2) %

All other (1)

21,152 17,623 20 % 55,330 50,316 10 %

Total 196,709 185,624 6 % 550,676 557,846 (1) %

(1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

Lifetime Value of Commissions per Approved Policy

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

(dollars per policy): 2026 2025 % Change 2026 2025 % Change

Medicare Advantage $ 904 $ 915 (1) % $ 871 $ 892 (2) %

All other(1)

81 151 (46) % 121 139 (13) %

(1) Represents the weighted average LTV per approved policy.

Healthcare Services

Financial Results

The following table provides the financial results for the Healthcare Services segment for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

(in thousands) 2026 2025 % Change 2026 2025 % Change

Revenue $ 199,386 $ 189,569 5 % $ 651,391 $ 528,677 23 %

Adjusted EBITDA 5,278 6,445 (18) % 13,336 13,534 (1) %

Adjusted EBITDA Margin 3 % 3 % 2 % 3 %

Operating Metrics

Members

The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

The following table shows the total number of SelectRx members as of the periods presented:

March 31, 2026 March 31, 2025

Total SelectRx Members 116,616 105,523

The total number of SelectRx members increased by 11% as of March 31, 2026, compared to March 31, 2025, due to our strategy to grow SelectRx membership.

The following table shows the average prescriptions shipped per day for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

2026 2025 2026 2025

Prescriptions Per Day

33,209 29,015 32,384 26,942

Combined Senior and Healthcare Services - Consumer Per Unit Economics

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

Twelve Months Ended March 31,

(dollars per approved policy): 2026 2025

MA and MS approved policies 582,951 616,379

MA and MS commission per MA / MS policy $ 868 $ 885

Other commission per MA/MS policy 11 13

Pharmacy revenue per MA/MS policy 1,461 1,063

Other revenue per MA/MS policy 150 103

Total revenue per MA / MS policy 2,490 2,064

Total operating expenses per MA / MS policy (2,193) (1,794)

Adjusted EBITDA per MA/MS policy $ 297 $ 270

Adjusted EBITDA Margin per MA/MS policy 12 % 13 %

Revenue / CAC multiple 6.7X 5.8X

Total revenue per MA/MS policy increased 21% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 22% for the twelve months ended March 31, 2026, compared to the twelve months ended March 31, 2025, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

(in thousands) 2026 2025 % Change 2026 2025 % Change

Revenue $ 47,896 $ 45,842 4 % $ 138,166 $ 124,993 11 %

Adjusted EBITDA 6,084 6,364 (4) % 17,236 19,747 (13) %

Adjusted EBITDA Margin 13 % 14 % 13 % 16 %

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

The following table shows term and final expense premiums for the periods presented:

Three Months Ended March 31, Nine Months Ended March 31,

(in thousands) 2026 2025 % Change 2026 2025 % Change

Term Premiums $ 19,123 $ 18,930 1 % $ 56,079 $ 51,459 9 %

Final Expense Premiums 27,287 27,681 (1) % 84,072 74,292 13 %

Total $ 46,410 $ 46,611 — % $ 140,151 $ 125,751 11 %

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community on May 5, 2026 beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://events.q4inc.com/analyst/775360431?pwd=VqmW7XWK. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income. We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income, is presented below on page 15. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company’s GAAP financial results.

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled

agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:

Sloan Bohlen

877-678-4083

investorrelations@selectquote.com

Media:

Matt Gunter

913-286-4931

matt.gunter@selectquote.com

Source: SelectQuote, Inc.

SELECTQUOTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands)

March 31, 2026 June 30, 2025

ASSETS

CURRENT ASSETS:

Cash, cash equivalents, and restricted cash $ 35,211 $ 35,733

Accounts receivable, net of allowances of $9.2 million and $11.8 million, respectively 234,291 151,388

Commissions receivable-current 76,836 132,077

Other current assets 20,900 21,844

Total current assets 367,238 341,042

COMMISSIONS RECEIVABLE—Net 882,693 818,751

PROPERTY AND EQUIPMENT—Net 13,247 14,577

SOFTWARE—Net 16,953 15,060

OPERATING LEASE RIGHT-OF-USE ASSETS 21,566 24,635

INTANGIBLE ASSETS—Net 1,120 1,973

GOODWILL 29,438 29,438

OTHER ASSETS 2,455 3,880

TOTAL ASSETS $ 1,334,710 $ 1,249,356

LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Accounts payable $ 103,205 $ 59,205

Accrued expenses 24,092 13,856

Accrued compensation and benefits 68,646 58,788

Operating lease liabilities—current 4,665 4,820

Current portion of long-term debt 22,457 68,523

Other current liabilities 8,035 7,718

Total current liabilities 231,100 212,910

LONG-TERM DEBT, NET—less current portion 353,326 316,589

DEFERRED INCOME TAXES 45,211 37,872

OPERATING LEASE LIABILITIES 22,678 25,982

OTHER LIABILITIES 18,904 80,485

Total liabilities 671,219 673,838

March 31, 2026 June 30, 2025

COMMITMENTS AND CONTINGENCIES

PREFERRED STOCK:

Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively, current liquidation preference of $408.4 million and $367.1 million as of March 31, 2026 and June 30, 2025. 278,757 224,374

SHAREHOLDERS’ EQUITY:

Common stock, $0.01 par value 1,763 1,728

Additional paid-in capital 526,129 571,605

Accumulated deficit (143,158) (222,189)

Total shareholders’ equity 384,734 351,144

TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY $ 1,334,710 $ 1,249,356

SELECTQUOTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands)

Three Months Ended March 31, Nine Months Ended March 31,

2026 2025 2026 2025

REVENUE:

Commissions and other services

$ 235,663 $ 222,889 $ 655,823 $ 663,338

Pharmacy 195,270 185,271 641,023 518,154

Total revenue 430,933 408,160 1,296,846 1,181,492

OPERATING COSTS AND EXPENSES:

Cost of commissions and other services revenue

83,268 79,412 255,403 246,283

Cost of goods sold—pharmacy revenue 171,289 162,304 569,262 448,029

Marketing and advertising 92,481 92,733 259,456 254,222

Selling, general, and administrative 38,188 41,685 112,948 122,850

Technical development 9,777 9,967 29,283 29,086

Total operating costs and expenses 395,003 386,101 1,226,352 1,100,470

INCOME FROM OPERATIONS 35,930 22,059 70,494 81,022

INTEREST EXPENSE, NET (10,602) (20,407) (34,023) (67,160)

CHANGE IN FAIR VALUE OF WARRANTS

27,489 32,986 61,821 25,344

LOSS ON EXTINGUISHMENT OF DEBT

(8,659) — (8,659) —

OTHER EXPENSE, NET (34) (37) (216) (70)

INCOME BEFORE INCOME TAX EXPENSE

44,124 34,601 89,417 39,136

INCOME TAX EXPENSE 3,927 8,579 10,386 4,424

NET INCOME $ 40,197 $ 26,022 $ 79,031 $ 34,712

Senior Non-Convertible Preferred Stock accumulated dividends and accretion

(18,775) (5,787) (54,382) (5,787)

NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS $ 21,422 $ 20,235 $ 24,649 $ 28,925

NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:

Basic $ 0.11 $ 0.11 $ 0.13 $ 0.17

Diluted $ 0.11 $ 0.03 $ 0.11 $ 0.13

WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:

Basic 189,455 178,156 187,614 173,462

Diluted 190,481 186,639 190,647 178,895

Three Months Ended March 31, Nine Months Ended March 31,

2026 2025 2026 2025

OTHER COMPREHENSIVE LOSS, NET OF TAX:

Unrealized loss, net of related tax benefit for the three and nine months ended March 31, 2026, and 2025, of $0.0 million and $0.1 million

— — — (432)

Amount reclassified into earnings, net of related tax benefit for the three months ended March 31, 2026, and 2025, of $0.0 million, and $0.0 million and for the nine months ended March 31, 2026, and 2025, of $0.0 million and $1.3 million.

— — — (3,680)

OTHER COMPREHENSIVE LOSS

— — — (4,112)

COMPREHENSIVE INCOME $ 40,197 $ 26,022 $ 79,031 $ 30,600

SELECTQUOTE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Nine Months Ended March 31,

2026 2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 79,031 $ 34,712

Adjustments to reconcile net income to net cash, cash equivalents, and restricted cash provided by operating activities:

Depreciation and amortization 13,007 15,584

Loss on disposal of property, equipment, and software — 160

Impairment of equity-method investment 1,000 —

Loss on extinguishment of debt

8,659 —

Share-based compensation expense 11,480 13,505

Deferred income taxes 7,340 4,424

Amortization of debt issuance costs and debt discount 3,343 3,880

Write-off of debt issuance costs — 93

Accrued interest payable in kind — 13,301

Change in fair value of warrants (61,821) (25,344)

Non-cash lease expense 3,070 2,849

Bad debt expense — 4,203

Changes in operating assets and liabilities:

Accounts receivable, net (82,903) (39,047)

Commissions receivable (8,702) (33,765)

Other assets 1,261 (343)

Accounts payable and accrued expenses 53,583 41,163

Operating lease liabilities (3,459) (3,574)

Other liabilities 10,315 (5,985)

Net cash provided by operating activities

35,204 25,816

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment (3,093) (1,690)

Purchases of software and capitalized software development costs (8,490) (6,513)

Net cash used in investing activities (11,583) (8,203)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from revolving credit facility 270,000 166,900

Payments on revolving credit facility (270,000) (166,900)

Net proceeds from Term Loan

315,234 —

Payments on Term Loans (314,000) (384,644)

Proceeds from ABS Notes — 99,095

Payments on ABS Notes (15,016) (11,723)

Payments on other debt (380) (202)

Proceeds from common stock options exercised and employee stock purchase plan — 112

Proceeds from issuance of Senior Non-Convertible Preferred Stock — 337,855

Senior Non-Convertible Preferred Stock issuance costs — (7,076)

Payments of tax withholdings related to net share settlement of equity awards (2,539) (5,019)

Payments of debt issuance costs

(7,730) (2,479)

Net cash (used in) provided by financing activities

(24,431) 25,919

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (810) 43,532

CASH, CASH EQUIVALENTS AND RESTRICTED CASH —Beginning of period 37,066 42,690

CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period $ 36,256 $ 86,222

SELECTQUOTE, INC. AND SUBSIDIARIES

Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense

(Unaudited)

Three Months Ended March 31, 2026

(in thousands) Senior Healthcare Services Life

Total

Total revenue from reportable segments $ 182,890 $ 199,386 $ 47,896 $ 430,172

Less:

Cost of commissions and other services revenue (54,596) (6,976) (18,465)

Cost of goods sold - pharmacy revenue — (169,814) —

Marketing expense (69,060) (1,686) (23,131)

Technical development — (318) —

Selling, general, and administrative (592) (15,314) (216)

Adjusted Segment EBITDA $ 58,642 $ 5,278 $ 6,084 $ 70,004

Reconciliation of total segment Adjusted EBITDA

All other Adjusted EBITDA 1,376

Corporate (26,790)

Share-based compensation expense (3,678)

Transaction costs (631)

Depreciation and amortization (4,385)

Loss on extinguishment of debt (8,659)

Change in fair value of warrants 27,489

Interest expense, net (10,602)

Income before income tax expense

$ 44,124

Three Months Ended March 31, 2025

(in thousands) Senior Healthcare Services Life

Total

Total revenue from reportable segments $ 169,442 $ 189,569 $ 45,842 $ 404,853

Less:

Cost of commissions and other services revenue (53,374) (5,816) (17,415)

Cost of goods sold - pharmacy revenue — (161,026) —

Marketing expense (69,808) (1,939) (21,789)

Technical development — (491) —

Selling, general, and administrative (559) (13,852) (274)

Adjusted Segment EBITDA $ 45,701 $ 6,445 $ 6,364 $ 58,510

Reconciliation of total segment Adjusted EBITDA

All other Adjusted EBITDA 3,549

Corporate (24,336)

Share-based compensation expense (4,960)

Transaction costs (5,813)

Depreciation and amortization (4,925)

Loss on disposal of property, equipment, and software, net (3)

Change in fair value of warrants 32,986

Interest expense, net (20,407)

Income before income tax expense

$ 34,601

SELECTQUOTE, INC. AND SUBSIDIARIES

Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense

(Unaudited)

Nine Months Ended March 31, 2026

(in thousands) Senior Healthcare Services Life

Total

Total revenue from reportable segments $ 503,426 $ 651,391 $ 138,166 $ 1,292,983

Less:

Cost of commissions and other services revenue (170,884) (21,635) (53,848)

Cost of goods sold - pharmacy revenue — (564,995) —

Marketing expense (190,746) (6,309) (66,267)

Technical development — (1,068) —

Selling, general, and administrative (1,739) (44,048) (815)

Adjusted Segment EBITDA $ 140,057 $ 13,336 $ 17,236 $ 170,629

Reconciliation of total segment Adjusted EBITDA

All other Adjusted EBITDA 5,366

Corporate (78,752)

Share-based compensation expense (11,480)

Transaction costs (1,478)

Depreciation and amortization (13,007)

Impairment of equity-method investment

(1,000)

Loss on extinguishment of debt (8,659)

Change in fair value of warrants 61,821

Interest expense, net (34,023)

Income before income tax expense

$ 89,417

Nine Months Ended March 31, 2025

(in thousands) Senior Healthcare Services Life

Total

Total revenue from reportable segments $ 517,930 $ 528,677 $ 124,993 $ 1,171,600

Less:

Cost of commissions and other services revenue (169,543) (19,627) (47,028)

Cost of goods sold - pharmacy revenue — (444,401) —

Marketing expense (192,583) (6,088) (57,456)

Technical development — (1,691) —

Selling, general, and administrative (1,855) (43,336) (762)

Adjusted Segment EBITDA $ 153,949 $ 13,534 $ 19,747 $ 187,230

Reconciliation of total segment Adjusted EBITDA

All other Adjusted EBITDA 9,645

Corporate (73,316)

Share-based compensation expense (13,505)

Transaction costs (13,358)

Depreciation and amortization (15,584)

Loss on disposal of property, equipment, and software, net (160)

Change in fair value of warrants 25,344

Interest expense, net (67,160)

Income before income tax expense

$ 39,136

RECONCILIATION OF NON-GAAP MEASURE

SELECTQUOTE, INC. AND SUBSIDIARIES

Reconciliation of Net income to Adjusted EBITDA

(Unaudited)

Three Months Ended March 31, Nine Months Ended March 31,

(in thousands) 2026 2025 2026 2025

Net income $ 40,197 $ 26,022 $ 79,031 $ 34,712

Share-based compensation expense 3,678 4,960 11,480 13,505

Transaction costs 631 5,813 1,478 13,358

Depreciation and amortization 4,385 4,925 13,007 15,584

Loss on disposal of property, equipment, and software, net — 3 — 160

Impairment of equity-method investment

— — 1,000 —

Loss on extinguishment of debt

8,659 — 8,659 —

Change in fair value of warrants (27,489) (32,986) (61,821) (25,344)

Interest expense, net 10,602 20,407 34,023 67,160

Income tax expense 3,927 8,579 10,386 4,424

Adjusted EBITDA $ 44,590 $ 37,723 $ 97,243 $ 123,559

EX-99.2

Filename: selectquoteincmarch31202.htm · Sequence: 3

selectquoteincmarch31202

| We shop. You save. 3rd Quarter Fiscal 2026 Earnings Presentation May 5, 2026 Exhibit 99.2

| We shop. You save. Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost- effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; our ability to regain and maintain compliance with NYSE listing standards; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, changes in reimbursement rates under our contracts with pharmacy benefit managers, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. No Offer or Solicitation; Further Information This presentation is for informational purposes only and is not an offer to sell with respect to any securities. This presentation should be read together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and the related notes thereto included in the Annual Report and subsequent quarterly reports. Non-GAAP Financial Measures This presentation includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this presentation Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, loss on extinguishment of debt, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure for Adjusted EBITDA is net income (loss). We monitor and have presented in this presentation Adjusted EBITDA because it is a key measure used by our management and Board of Directors in understanding and evaluating our operating performance, establishing budgets, and developing operational goals for managing our business. In particular, we believe that excluding the impact of certain expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. For further discussion regarding this non-GAAP measure, please see today’s press release. A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP financial measure, net income (loss), is set forth below on slide 11. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain items included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company's GAAP financial results. Disclaimer 2

| We shop. You save. 3Q Earnings Highlights 3 • Consolidated ◦ Revenue increased 6% and Adjusted EBITDA* increased 18% year-over-year, driven by continued Healthcare Services growth and a strong Senior OEP • Senior ◦ Adjusted EBITDA increased 28% year-over-year to $59 million in 3Q, including a positive change in estimate of $14 million to commissions receivable ◦ Solid agent productivity and marketing efficiency yielded 32% Adjusted EBITDA margins ◦ Existing customer and new customer retention improved year-to-date in 2026 • Healthcare Services ◦ 3Q Adjusted EBITDA increased to $5 million as PBM reimbursement rates increased on January 1st ◦ Revenue grew 5% year-over-year to $199 million despite Inflation Reduction Act impacts • SelectQuote Local ◦ Leverages industry-leading marketing, technology, customer service, and carrier relationships to offer Senior and Life products through a franchising model with local sales and service *See "Non-GAAP Financial Measures" section on slide 2

| We shop. You save. 3Q24 3Q25 3Q26 3Q24 3Q25 3Q26 4.2x 5.8x 6.7x 3Q24 3Q25 3Q26 20k 29k 33k 3Q24 3Q25 3Q26 Prescriptions Per DayAgent Productivity† Revenue / CAC** †Percentage change deltas are calculated relative to 3Q24 results. *Represents total Senior division marketing expenses per approved Medicare Advantage and Medicare Supplement policy. Marketing Expense Per Policy*† 1% 14% 4 **The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition costs for the Senior and Healthcare Services divisions, which represents the direct costs of acquiring leads. Senior Healthcare Services Execution Fuels Cash Flow Generation

| We shop. You save. • Revenue growth driven by Healthcare Services, strong Senior OEP results, and a positive change in estimate • Adjusted EBITDA* of $45 million increased 18% year-over-year • Robust 32% Senior Adjusted EBITDA margins, inclusive of $14 million change in estimate $408 $431 3Q25 3Q26 Consolidated Financial Summary *See "Non-GAAP Financial Measures" section on slide 2 Commentary $38 $45 3Q25 3Q26 5 Revenue $MM Adjusted EBITDA* $MM

| We shop. You save. $169 $183 3Q25 3Q26 Revenue $MM Adjusted EBITDA $MM Senior Financial Summary Commentary $46 $59 3Q25 3Q26 27% 32% • Senior revenue of $183 million, up 8% year-over-year • Adjusted EBITDA increased year- over-year to $59 million • $14 million change in estimate to commissions receivable • Strong 32% Adjusted EBITDA margins 6

| We shop. You save. SELECTRX Members 106 108 107 113 117 3Q25 4Q25 1Q26 2Q26 3Q26 0 20 40 60 80 100 120 140 Revenue & Adjusted EBITDA $MM $6 $12 $7 $1 $5 $190 $214 $221 $231 $199 3Q25 4Q25 1Q26 2Q26 3Q26 Healthcare Services KPIs REVENUE ADJUSTED EBITDA 7

| We shop. You save. • Revenue increased 4% year-over- year driven by continued strong Final Expense performance • Adjusted EBITDA remained steady year-over-year in 3Q $6 $6 3Q25 3Q26 $46 $48 3Q25 3Q26 Life Financial Summary Adjusted EBITDA $MM Commentary Revenue $MM 8

| We shop. You save. Reiterating FY26 Financial Guidance REVENUE $1.61B ADJUSTED EBITDA* to $1.71B $90M to $100M *See "Non-GAAP Financial Measures" above on slide 2. 9

| We shop. You save. Supplemental Information 10

| We shop. You save. Reconciliation of Non-GAAP Measure Reconciliation of Net Income to Adjusted EBITDA 11 3Q FY FY YTD (in thousands) 2026 2025 2026 2025 Net income $ 40,197 $ 26,022 $ 79,031 $ 34,712 Share-based compensation expense 3,678 4,960 11,480 13,505 Transaction costs 631 5,813 1,478 13,358 Depreciation and amortization 4,385 4,925 13,007 15,584 Loss on disposal of property, equipment, and software, net — 3 — 160 Impairment of equity-method investment — — 1,000 — Loss on extinguishment of debt 8,659 — 8,659 — Change in fair value of warrants (27,489) (32,986) (61,821) (25,344) Interest expense, net 10,602 20,407 34,023 67,160 Income tax expense 3,927 8,579 10,386 4,424 Adjusted EBITDA $ 44,590 $ 37,723 $ 97,243 $ 123,559

| We shop. You save. 3Q FY 2026 (in thousands) Senior Healthcare Services Life Total Total revenue from reportable segments $ 182,890 $ 199,386 $ 47,896 $ 430,172 Less: Cost of commissions and other services revenue (54,596) (6,976) (18,465) Cost of goods sold - pharmacy revenue — (169,814) — Marketing expense (69,060) (1,686) (23,131) Technical development — (318) — Selling, general, and administrative (592) (15,314) (216) Adjusted Segment EBITDA $ 58,642 $ 5,278 $ 6,084 $ 70,004 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 1,376 Corporate (26,790) Share-based compensation expense (3,678) Transaction costs (631) Depreciation and amortization (4,385) Loss on extinguishment of debt (8,659) Change in fair value of warrants 27,489 Interest expense, net (10,602) Income before income tax expense $ 44,124 Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense 12

| We shop. You save. 3Q FY 2025 (in thousands) Senior Healthcare Services Life Total Total revenue from reportable segments $ 169,442 $ 189,569 $ 45,842 $ 404,853 Less: Cost of commissions and other services revenue (53,374) (5,816) (17,415) Cost of goods sold - pharmacy revenue — (161,026) — Marketing expense (69,808) (1,939) (21,789) Technical development — (491) — Selling, general, and administrative (559) (13,852) (274) Adjusted Segment EBITDA $ 45,701 $ 6,445 $ 6,364 $ 58,510 Reconciliation of total segment Adjusted EBITDA All other Adjusted EBITDA 3,549 Corporate (24,336) Share-based compensation expense (4,960) Transaction costs (5,813) Depreciation and amortization (4,925) Loss on disposal of property, equipment, and software, net (3) Change in fair value of warrants 32,986 Interest expense, net (20,407) Income before income tax expense $ 34,601 Reconciliation by Segment of Adjusted EBITDA to Income before income tax expense 13

| We shop. You save. SelectQuote Inc. 6800 West 115th Street Suite 2511 Overland Park, Kansas 66211 Phone: (877) 678-4086 Investor Relations investorrelations@selectquote.com 14

GRAPHIC

Filename: selectquoteincmarch31202001.jpg · Sequence: 7

Binary file (114635 bytes)

Download selectquoteincmarch31202001.jpg

GRAPHIC

Filename: selectquoteincmarch31202002.jpg · Sequence: 8

Binary file (278916 bytes)

Download selectquoteincmarch31202002.jpg

GRAPHIC

Filename: selectquoteincmarch31202003.jpg · Sequence: 9

Binary file (136629 bytes)

Download selectquoteincmarch31202003.jpg

GRAPHIC

Filename: selectquoteincmarch31202004.jpg · Sequence: 10

Binary file (89245 bytes)

Download selectquoteincmarch31202004.jpg

GRAPHIC

Filename: selectquoteincmarch31202005.jpg · Sequence: 11

Binary file (83630 bytes)

Download selectquoteincmarch31202005.jpg

GRAPHIC

Filename: selectquoteincmarch31202006.jpg · Sequence: 12

Binary file (76050 bytes)

Download selectquoteincmarch31202006.jpg

GRAPHIC

Filename: selectquoteincmarch31202007.jpg · Sequence: 13

Binary file (73209 bytes)

Download selectquoteincmarch31202007.jpg

GRAPHIC

Filename: selectquoteincmarch31202008.jpg · Sequence: 14

Binary file (65320 bytes)

Download selectquoteincmarch31202008.jpg

GRAPHIC

Filename: selectquoteincmarch31202009.jpg · Sequence: 15

Binary file (56034 bytes)

Download selectquoteincmarch31202009.jpg

GRAPHIC

Filename: selectquoteincmarch31202010.jpg · Sequence: 16

Binary file (31598 bytes)

Download selectquoteincmarch31202010.jpg

GRAPHIC

Filename: selectquoteincmarch31202011.jpg · Sequence: 17

Binary file (77689 bytes)

Download selectquoteincmarch31202011.jpg

GRAPHIC

Filename: selectquoteincmarch31202012.jpg · Sequence: 18

Binary file (86522 bytes)

Download selectquoteincmarch31202012.jpg

GRAPHIC

Filename: selectquoteincmarch31202013.jpg · Sequence: 19

Binary file (87714 bytes)

Download selectquoteincmarch31202013.jpg

GRAPHIC

Filename: selectquoteincmarch31202014.jpg · Sequence: 20

Binary file (99792 bytes)

Download selectquoteincmarch31202014.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 22

v3.26.1

Cover

May 05, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

May 05, 2026

Entity Registrant Name

SELECTQUOTE, INC.

Entity Incorporation, State or Country Code

Entity File Number

001-39295

Entity Tax Identification Number

94-3339273

Entity Address, Address Line One

6800 West 115th Street

Entity Address, Address Line Two

Suite 2511

Entity Address, City or Town

Overland Park

Entity Address, State or Province

Entity Address, Postal Zip Code

66211

City Area Code

913

Local Phone Number

599-9225

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

SLQT

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001794783

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration